Healthcare Equipment and Supplies
Company Overview of NeoTract, Inc.
NeoTract, Inc. develops and manufactures medical devices for urologists. It offers UroLift System, a minimally invasive device to treat lower urinary tract symptoms due to benign prostatic hyperplasia. The company was incorporated in 2004 and is based in Pleasanton, California.
4473 Willow Road
Pleasanton, CA 94588
Founded in 2004
Key Executives for NeoTract, Inc.
Chief Executive Officer, President and Director
Founder, Chief Technical Officer and Director
Co-Founder and Vice President of Research & Development
Compensation as of Fiscal Year 2014.
NeoTract, Inc. Key Developments
NeoTract, Inc. Presents at Medical Device Conference 2015, Jun-25-2015 through Jun-26-2015
Jun 22 15
NeoTract, Inc. Presents at Medical Device Conference 2015, Jun-25-2015 through Jun-26-2015. Venue: Palace Hotel, 2 New Montgomery Street, San Francisco, California, United States. Presentation Date & Speakers: Jun-26-2015, David Amerson, Chief Executive Officer, President and Director.
NeoTract, Inc. Presents at International Business Forum 14th Annual MedTech Investing Conference, May-06-2015 02:20 PM
May 3 15
NeoTract, Inc. Presents at International Business Forum 14th Annual MedTech Investing Conference, May-06-2015 02:20 PM. Venue: Loews Minneapolis Hotel, 601, 1st Ave North, Minneapolis, MN 55403, United States. Speakers: Dave Amerson, President & CEO.
NeoTract Announces Positive Guidelines from European Association of Urology for Minimally Invasive Treatment for Benign Prostatic Hyperplasia
Apr 30 15
NeoTract, Inc. announced that the European Association of Urology (EAU) has given the UroLift® System a positive recommendation for the treatment of patients with benign prostatic hyperplasia (BPH) in its newly updated ‘Guidelines for the Management of Non-Neurogenic Male Lower Urinary Tract Symptoms, Including Benign Prostatic Obstruction,’ published in European Urology The guidelines assist practicing urologists in Europe in making informed decisions based on the highest-quality scientific data. The guidelines and recommendations were based on a rigorous systematic review of the published literature on the UroLift System, performed by a panel of experts with urological and epidemiological backgrounds. The review panel graded the clinical evidence supporting the UroLift device Level 1-b, the second-highest level of evidence, denoting evidence obtained from at least one properly designed randomized controlled trial that suggests that the benefits of the clinical service outweigh the potential risks. Three-year results of the L.I.F.T. IDE Study, a multi-center, randomized, blinded U.S. clinical trial, as well as one-year results from the randomized BPH-6 European multi-center randomized study comparing UroLift to transurethral resection of the prostate (TURP), will be presented at the American Urological Association’s annual conference taking place May 15-19 in New Orleans. The UroLift device has received regulatory clearance in the United States, is CE marked in Europe, and is currently available in Denmark, Finland, France, Germany, Italy, The Netherlands, Norway, Spain, Sweden, Turkey and the United Kingdom.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|